Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. - Wikidata - awgldk - TriplyDB

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

http://www.wikidata.org/entity/Q34896252

about

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Clinical outcome of patients with pancreatic metastases from renal cell cancer A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy Postoperative surveillance imaging for patients undergoing nephrectomy for renal cell carcinoma Sulforaphane inhibits proliferation and invasive activity of everolimus-resistant kidney cancer cells in vitro.The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Novel therapeutic options for second-line therapy in metastatic renal cell carcinoma.Different clinicopathological features between patients who developed early and late recurrence following surgery for renal cell carcinoma.The blind spots in follow-up after nephrectomy or nephron-sparing surgery for localized renal cell carcinoma.Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up.Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.A CARP-1 functional mimetic loaded vitamin E-TPGS micellar nano-formulation for inhibition of renal cell carcinoma.Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience.Inherent characteristics of metachronous metastatic renal cell carcinoma in the era of targeted agents.[Focal therapy for small renal masses : Observation, ablation or surgery].Clinicopathological features and outcomes in patients with late recurrence of renal cell carcinoma after radical surgery.

P2860

Q28072166-7AA8EF13-63D0-45AD-B274-61608D31AAF4 Q33758217-0B26D308-6491-4E12-B652-5693A5E1C6A2 Q34495684-A71B6C12-B3FA-4EA1-B9FE-0F57C06824DD Q35083485-FB4936F6-08C5-4336-AD85-E50DFE059C1D Q35095830-6F4C497E-7EF4-4349-A1E7-4FF0153669DB Q36092829-6DDC8D24-38F2-4FA7-8460-28E7DFF4DDCE Q36303564-E0DA588C-D6CD-40BF-ABDF-54941478E099 Q37709114-E9F3AD94-F216-49F9-A8EF-1B4AECA809CE Q38202060-2C76368D-FC3D-4117-B5D7-A2CDD77C16E2 Q38794217-F9F4FD44-EF25-4CA4-ADA4-D57FC5A962A8 Q38868038-786DBC0C-01F7-49F5-9E00-2A9A505B255F Q39090533-1F98852B-B8ED-4051-B3FE-0148FC3E4B66 Q39136550-D6B8BF47-31BD-45DC-91E8-E89D8BE7F0B4 Q40322702-6D6F10F3-D729-4EA4-A589-1054AD4EC933 Q41624982-CD82DCDB-B71B-49FC-819A-692854ADE3F8 Q46106579-E44D4049-4379-4C4B-A0B9-4252379B866E Q47132952-E1CFFFFA-7B29-4C44-88A1-8A91B44A483B Q47149978-F135EDBB-DBA9-4BDD-86FC-4CECB02F7B46 Q47158686-B4C247B1-DE52-4352-A8CC-0C836E9E8484 Q50240365-06954CD6-8B9A-47D0-9DD4-933C4312E710 Q51788363-D0B4BCA9-EC9E-4B59-B612-68DD68429467

P2860

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

http://www.wikidata.org/entity/Q34896252

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Survival outcome and treatment ...... n the era of targeted therapy.

@ast

Survival outcome and treatment ...... n the era of targeted therapy.

@en

Survival outcome and treatment ...... n the era of targeted therapy.

@nl

type

label

Survival outcome and treatment ...... n the era of targeted therapy.

@ast

Survival outcome and treatment ...... n the era of targeted therapy.

@en

Survival outcome and treatment ...... n the era of targeted therapy.

@nl

prefLabel

Survival outcome and treatment ...... n the era of targeted therapy.

@ast

Survival outcome and treatment ...... n the era of targeted therapy.

@en

Survival outcome and treatment ...... n the era of targeted therapy.

@nl

P1433

Q34896252-857FA324-8316-4E68-8981-16FDC184730F

P1476

Q34896252-CC824D5B-FC2A-47B7-BEB9-AB66612ECAEA

P2093

Q34896252-142BF706-1DFC-4F35-8ECB-046E789C03E0

Q34896252-212F31B8-C5BF-4952-8E25-3CF36A339B24

Q34896252-212F98D3-F428-4851-BDA6-01BF4C838F27

Q34896252-34E5C216-C6D2-4392-942D-D8940D758412

Q34896252-39B2AD39-BDDD-4735-A2E7-6472B78725BD

Q34896252-3FDEA0C7-4CEE-4F18-8A29-9D8690B4CE59

Q34896252-4FEC7157-1A02-4014-8C89-A8C189723D1E

Q34896252-51459DB3-86F9-437D-A7A9-97C2E8AED647

Q34896252-5DBEA93B-DAEA-4AAA-9D0C-5E1A2F9DBE90

Q34896252-68CC23A8-E134-42F5-88C5-3F76948B8ED9

P304

Q34896252-BDAD9855-5402-4AA5-A145-B924E149FF44

P31

Q34896252-2B0E4E4E-7E0D-48DA-AF54-F30E98EB57B5

P356

Q34896252-14E34759-E2B7-4217-906B-3B87AE3D0439

P407

Q34896252-6B2B615B-8DCE-4852-9A98-68E2AE46E69F

P433

Q34896252-3930CBEC-1BCD-4EA4-913B-E6226C1D7371

P478

Q34896252-988EA7DE-1BCC-4E3F-9F60-A7112ABEE1A0

P50

Q34896252-5D4E2DB4-2B1E-421B-BB59-FA4B72E9A9E9

Q34896252-8F68A335-9140-421B-A3E2-C47B7DF09150

Q34896252-AC7DBC87-D7DF-4A9E-B3AD-C60E4107ACC6

P577

Q34896252-5908C197-7480-45F0-983F-C3DDD25800C1

P5875

Q34896252-3BCC122E-2772-400F-AC38-261F4B7FE44E

P698

Q34896252-90C55022-0CC7-403C-B503-579E261B4307

P356

J.EURURO.2013.07.031

P1433

European Urology

P1476

Survival outcome and treatment ...... in the era of targeted therapy

@en

P2093

Aristotelis Bamias

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Christian K Kollmannsberger

http://www.w3.org/2001/XMLSchema#string

Daniel Y C Heng

http://www.w3.org/2001/XMLSchema#string

Jae-Lyn Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer J Knox

http://www.w3.org/2001/XMLSchema#string

Lori Wood

http://www.w3.org/2001/XMLSchema#string

Mary J MacKenzie

http://www.w3.org/2001/XMLSchema#string

Min-Han Tan

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

P304

1086-1092

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2013.07.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Georg A. Bjarnason

P577

2013-07-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255690552

http://www.w3.org/2001/XMLSchema#string

P698

23916693

http://www.w3.org/2001/XMLSchema#string